Today's market saw significant declines, particularly among leveraged exchange-traded funds (ETFs) and specific company stocks. These drops are tied to various factors, including anticipation of earnings reports, high short interest, corporate actions, and legal investigations that are influencing investor behavior and driving high trading volumes.
The downturn was led by ETFs linked to Tesla (NASDAQ: TSLA). The Direxion Daily TSLA Bull 2X ETF (NASDAQ:TSLL) fell 29.20% to $7.76, while the GraniteShares 2x Long TSLA Daily ETF (NASDAQ:TSLR) dropped 29.02% to $13.37. These funds are designed to double Tesla's daily performance, so a drop in the stock causes a much larger fall for the ETF. The decline comes as investors await Tesla's upcoming earnings report, as highlighted by ETF Trends.
Adding to the pressure, GraniteShares 2x Long TSLA Daily ETF experienced a 50.2% rise in short interest, as reported by Defense World. Short interest represents shares sold by investors betting the price will fall, indicating a growing negative outlook. Separately, the Daily Target 2X Long QS ETF (NASDAQ:QSU) fell 25.58% to $5.63. This fund is undergoing a reverse stock split, an action that reduces share count to raise the share price without changing an investment's total value, as announced by GlobeNewsWire.
In the energy sector, Liberty Energy Inc. (NYSE:LBRT) saw its shares fall 21.96% to $19.62. This occurred even though the company beat earnings estimates, as its earnings per share of $0.09 were lower than the previous year, according to Zacks Investment Research. Meanwhile, Shutterstock, Inc. (NYSE:SSTK) dropped 21.95% to $5.76. This decline follows news from PRNewsWire that an investigation is being conducted on behalf of the company's investors.
In summary, the day's market losers were impacted by a range of specific events. These included investor caution ahead of major earnings, increased bets against a stock, corporate restructuring like stock splits, and the announcement of legal investigations, all contributing to significant price drops.
